Depression is a major mental health issue worldwide, with high rates of chronicity and non-recovery associated with the condition. Existing treatments such as antidepressant medication and psychological treatments have modest effectiveness, suggesting the need for alternative interventions.
Aim:
The aim of this study was to examine the relationships between MDMA (3,4-methylenedioxymethamphetamine)/ecstasy and psilocybin use and major depressive episodes (MDEs).
Methods:
This observational study used data from a large (N = 213,437) nationally representative sample of US adults to test the association of lifetime use of MDMA/ecstasy, psilocybin and other classic psychedelics (lysergic acid diethylamide (LSD), peyote, mescaline), other illegal substances (e.g. cocaine, phencyclidine (PCP)), and legal/medicinal substances of misuse (e.g. pain relievers, tranquilizers) with lifetime, past year, and past year severe MDEs.
Results:
Results revealed that lifetime MDMA/ecstasy use was associated with significantly lowered odds of a lifetime MDE (adjusted odds ratio (aOR) = 0.84; p < 0.001), past year MDE (aOR = 0.84; p < 0.001), and past year severe MDE (aOR = 0.82; p < 0.001). Psilocybin was associated with significantly lowered odds of a past year MDE (aOR = 0.90; p < 0.05) and past year severe MDE (aOR = 0.87; p < 0.05). All other substances either shared no relationship with a MDE or conferred increased odds of an MDE.
Conclusions:
These results suggest that MDMA/ecstasy and psilocybin use is associated with lower risk of depression. Experimental studies are needed to test whether there is a causal association between use of these compounds and the alleviation of depressive symptoms.
Agin-LiebesGIMaloneTYalchMM, et al. (2020) Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology34(2): 155–166.
2.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association.
3.
Carhart-HarrisRGiribaldiBWattsR, et al. (2021) Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine384(15): 1402–1411.
4.
Carhart-HarrisRRosemanLHaijenE, et al. (2018) Psychedelics and the essential importance of context. Journal of Psychopharmacology32(7): 725–731.
5.
ChoiNGDiNittoDMMartiCN, et al. (2016) Relationship between marijuana and other illicit drug use and depression/suicidal thoughts among late middle-aged and older adults. International Psychogeriatrics28(4): 577–589.
6.
ClemensKJMcGregorISHuntGE, et al. (2007) MDMA, methamphetamine and their combination: Possible lessons for party drug users from recent preclinical research. Drug and Alcohol Review26(1): 9–15.
7.
DavisAKBarrettFSMayDG, et al. (2021) Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry78: 481–489.
8.
FarréMAbanadesSRosetPN, et al. (2007) Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: Pharmacological effects and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics323(3): 954.
9.
GasserPHolsteinDMichelY, et al. (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. The Journal of Nervous and Mental Disease202(7): 513–520.
10.
GorskaAMKamińskaKWawrzczak-BargiełaA, et al. (2018) Neurochemical and neurotoxic effects of MDMA (ecstasy) and caffeine after chronic combined administration in mice. Neurotoxicity Research33(3): 532–548.
11.
GreenARMechanAOElliottJM, et al. (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacological Reviews55(3): 463–508.
12.
GriffithsRRJohnsonMWCarducciMA, et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology30(12): 1181–1197.
13.
GriffithsRRRichardsWAMcCannU, et al. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology187(3): 268–283.
14.
GrobCSDanforthALChopraGS, et al. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry68(1): 71.
15.
HavardATeessonMDarkeS, et al. (2006) Depression among heroin users: 12-month outcomes from the Australian Treatment Outcome Study (ATOS). Journal of Substance Abuse Treatment30(4): 355–362.
16.
HendricksPSCrawfordMSCropseyKL, et al. (2018) The relationships of classic psychedelic use with criminal behavior in the United States adult population. Journal of Psychopharmacology32(1): 37–48.
17.
HendricksPSJohnsonMWGriffithsRR (2015a) Psilocybin, psychological distress, and suicidality. Journal of Psychopharmacology29(9): 1041–1043.
18.
HendricksPSThorneCBClarkCB, et al. (2015b) Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology29(3): 280–288.
19.
JeromeLFeducciaAAWangJB, et al. (2020). Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: A longitudinal pooled analysis of six phase 2 trials. Psychopharmacology237(8): 2485–2497.
20.
JohnsonCSStansfieldCRHassanVR (2020) Festival testing: A survey of suspected drugs seized from New Zealand music festivals, December 2018 to March 2019. Forensic Science International313: 110367.
21.
JonesGNockMK (in press) MDMA/ecstasy and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of U.S adults. Journal of Psychopharmacology.
22.
KesslerRCMerikangasKR (2004) The National Comorbidity Survey Replication (NCS-R): Background and aims. International Journal of Methods in Psychiatric Research13(2): 60–68.
23.
KovácsGGAndóRDAdoriC, et al. (2007) Single dose of MDMA causes extensive decrement of serotoninergic fibre density without blockage of the fast axonal transport in Dark Agouti rat brain and spinal cord. Neuropathology and Applied Neurobiology33(2): 193–203.
24.
LernerMLyversM (2006) Values and beliefs of psychedelic drug users: A cross-cultural study. Journal of Psychoactive Drugs38(2): 143–147.
25.
LiechtiMEGammaAVollenweiderFX (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology154(2): 161–168.
LyversMMeesterM (2012) Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner. Journal of Psychoactive Drugs44(5): 410–417.
28.
MahapatraAGuptaR (2017) Role of psilocybin in the treatment of depression. Therapeutic Advances in Psychopharmacology7(1): 54–56.
29.
MajumderIWhiteJMIrvineRJ (2011) Antidepressant-like effects of 3,4-methylenedioxymethamphetamine in an animal model of depression. Behavioural Pharmacology22(8): 758–765.
30.
MajumderIWhiteJMIrvineRJ (2012) Antidepressant-like effects of ecstasy in subjects with a predisposition to depression. Addictive Behaviors37(10): 1189–1192.
31.
MeyerJSGrandeMJohnsonK, et al. (2004) Neurotoxic effects of MDMA (“ecstasy”) administration to neonatal rats. International Journal of Developmental Neuroscience: The Official Journal of the International Society for Developmental Neuroscience22(5–6): 261–271.
32.
MithoeferMCFeducciaAAJeromeL, et al. (2019) MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology236(9): 2735–2745.
33.
MithoeferMCWagnerMTMithoeferAT, et al. (2011) The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. Journal of Psychopharmacology25(4): 439–452.
34.
MithoeferMCWagnerMTMithoeferAT, et al. (2013) Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study. Journal of Psychopharmacology27(1): 28–39.
35.
MóróLSimonKBárdI, et al. (2011) Voice of the psychonauts: Coping, life purpose, and spirituality in psychedelic drug users. Journal of Psychoactive Drugs43(3): 188–198.
36.
NourMMEvansLCarhart-HarrisR (2017) Psychedelics, personality and political perspectives. Journal of Psychoactive Drugs49(3): 182–191.
37.
OehenPTraberRWidmerV, et al. (2013) A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). Journal of Psychopharmacology27(1): 40–52.
38.
OsórioFdeLSanchesRF, et al. (2015) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A preliminary report. Revista Brasileira de Psiquiatria37(1): 13–20.
39.
Ot’aloraGMGrigsbyJPoulterB, et al. (2018) 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. Journal of Psychopharmacology32(12): 1295–1307.
40.
Palhano-FontesFBarretoDOniasH, et al. (2019) Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychological Medicine49(4): 655–663.
41.
PantoniMMAnagnostarasSG (2019) Cognitive effects of MDMA in laboratory animals: A systematic review focusing on dose. Pharmacological Reviews71(3): 413–449.
42.
PatelRTitheradgeD (2015) MDMA for the treatment of mood disorder: All talk no substance?Therapeutic Advances in Psychopharmacology5(3): 179–188.
43.
SaleemiSPennybakerSJWooldridgeM, et al. (2017) Who is “Molly”? MDMA adulterants by product name and the impact of harm-reduction services at raves. Journal of Psychopharmacology31(8): 1056–1060.
44.
SextonJDNicholsCDHendricksPS (2020) Population survey data informing the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics. Frontiers in Psychiatry10: 896.
45.
SheehanDVHarnett-SheehanKRajBA (1996) The measurement of disability. International Clinical Psychopharmacology, Suppl113: 89–95.
46.
SimonssonOSextonJDHendricksPS (2021) Associations between lifetime classic psychedelic use and markers of physical health. Journal of Psychopharmacology35: 447–452.
47.
SordoLChahuaMBravoMJ, et al. (2012) Depression among regular heroin users: The influence of gender. Addictive Behaviors37(1): 148–152.
48.
ter BogtTFMEngelsRCMEDubasJS (2006) Party people: Personality and MDMA use of house party visitors. Addictive Behaviors31(7): 1240–1244.
49.
TurnerEHMatthewsAMLinardatosE, et al. (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine358(3): 252–260.
50.
United States Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (2014) National survey on drug use and health, 2014. Available at: https://datafiles.samhsa.gov/
51.
United States Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (2015) National survey on drug use and health, 2015. Available at: https://datafiles.samhsa.gov/
52.
United States Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (2016) National survey on drug use and health, 2016. Available at: https://datafiles.samhsa.gov/
53.
United States Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (2017) National survey on drug use and health, 2017. Available at: https://datafiles.samhsa.gov/
54.
United States Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (2018) National survey on drug use and health, 2018. Available at: https://datafiles.samhsa.gov/
55.
Van OekelenDLuytenWHMLLeysenJE (2003) 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sciences72(22): 2429–2449.
56.
Van RandenborghAHüffmeierJVictorD, et al. (2012) Contrasting chronic with episodic depression: An analysis of distorted socio-emotional information processing in chronic depression. Journal of Affective Disorders141(2–3): 177–184.
57.
Vanattou-SaïfoudineNMcNamaraRHarkinA (2012) Caffeine provokes adverse interactions with 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) and related psychostimulants: Mechanisms and mediators. British Journal of Pharmacology167(5): 946–959.
58.
VollenweiderFXKometerM (2010) The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nature Reviews Neuroscience11(9): 642–651.
59.
WeiszJRMcCartyCAValeriSM (2006) Effects of psychotherapy for depression in children and adolescents: A meta-analysis. Psychological Bulletin132(1): 132–149.
ZeifmanRJPalhano-FontesFHallakJ, et al. (2019) The impact of ayahuasca on suicidality: Results from a randomized controlled trial. Frontiers in Pharmacology10: 1325.
63.
ZeifmanRJSinghalNDos SantosRG, et al. (2021) Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: Results from an open-label trial. Psychopharmacology238(2): 453–459.
